Mallinckrodt plc has announced that the Irish High Court has granted the necessary ruling to proceed with its merger with Endo, Inc. This development follows shareholder approval from both companies and represents the final substantive legal requirement for the transaction. The merger, expected to close in early August, will create a global therapeutics leader with Mallinckrodt's Dublin headquarters serving as the combined company's global base. Siggi Olafsson, CEO of Mallinckrodt, who will lead the new entity, emphasized the opportunity to accelerate value creation for stakeholders and enhance patient care. After the merger, the companies plan to merge their generic pharmaceuticals businesses and Endo's sterile injectables business, with a possible future separation subject to board approval.